
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc. has demonstrated solid financial performance, with Cell Processing revenue growing 12% year-over-year to $73.5 million in 2024 and a sequential increase of 7% to $20.3 million in the fourth quarter of 2024. The company has raised its FY24 guidance for Cell Processing, now estimating revenue between $72 million and $73 million, and projecting continued robust growth into FY25, with anticipated revenue between $82 million and $85 million, representing a 15% year-over-year increase. Additionally, increased demand for its biopreservation media, coupled with strategic divestitures enhancing gross margins, positions the company for strong long-term growth, with management expecting gross margins in the low 60% range and total revenue for 2025 projected at $95.5 million to $99 million, reflecting a 16-20% year-over-year growth outlook.
Bears say
BioLife Solutions Inc. faces multiple risks that contribute to a negative outlook, including the potential for lower-than-projected growth in its bioproduction products and services, as well as challenges in securing additional customers. The company reported a net loss of $11.4 million, equating to a loss of $0.25 per share, which raises concerns about its financial sustainability. Additionally, risks associated with fluctuations in sales in emerging markets, foreign exchange rates, and manufacturing or supply chain disruptions further exacerbate uncertainties surrounding its revenue generation and operational stability.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares